MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Orexigen Therapeutics Company Profile (NASDAQ:OREX)

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 1 Sell Rating(s), 7 Hold Rating(s)
Consensus Rating:Hold (Score: 1.88)
Consensus Price Target: $2.67 (494.18% upside)

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetActions
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Piper JaffrayDowngradeOverweight -> Neutral$5.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016RBC CapitalDowngradeOutperform -> Sector Perform$5.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/12/2015Bank of AmericaReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2015Wells FargoDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit SuisseInitiated CoverageOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.21)($0.21)$1.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.20)($0.23)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.09)($0.09)($0.09)
Q2 20162($0.14)($0.10)($0.12)
Q3 20162($0.18)($0.10)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)
Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
DateHeadline
06/25/16 09:24 AMAnalyst's Stocks Rating Activity: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) , Orexigen Therapeutics, Inc ... - Street Updates
06/23/16 06:13 PMRecently Issued Stock Ratings For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Fiscal Standard
06/21/16 10:03 AMOrexigen - Contrave Sales Present Troubling Data - Seeking Alpha
06/20/16 05:28 PMThis Weeks Broker Views For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Fiscal Standard
06/20/16 05:28 PMStrong Buy Calls Count For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire
06/20/16 07:17 AMCompany Shares of Orexigen Therapeutics Drops by -0.13% - Trade Calls
06/17/16 08:27 AMRecent Trading Updates: Orexigen Therapeutics, Inc. (NASDAQ:OREX) , Stryker Corporation (NYSE:SYK) - Street Updates
06/16/16 05:54 PMOrexigen Therapeutics : Reports Favorable Markman Ruling in Contrave® Patent Litigation
06/15/16 05:38 PMEarnings in Focus: DENTSPLY International Inc. (NASDAQ:XRAY), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Beacon Chronicle
06/14/16 05:25 PMPrice Target by Brokers: Orexigen Therapeutics, Inc. (NASDAQ:OREX), TOTAL S.A. (NYSE:TOT) - Beacon Chronicle
06/13/16 08:39 AMHC Stocks Broker Alerts: Pacific Biosciences of California (NASDAQ:PACB), Orexigen Therapeutics, Inc. (NASDAQ ... - share market updates (press release)
06/11/16 08:33 AMOrexigen Therapeutics Inc. (OREX) Drops 19.82% on June 09 - Equities.com
06/10/16 08:39 AMAnalyst Recommendations Review: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - News Oracle
06/10/16 08:39 AMHC Stocks Reports: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - share market updates (press release)
06/10/16 08:39 AMTake a look at Analyst Tips: Orexigen Therapeutics, Inc. (NASDAQ:OREX) , Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Street Updates
06/09/16 06:01 PMNASDAQ Unusual Volume: Gevo, Inc. (NASDAQ:GEVO), Orexigen Therapeutics, Inc. (NASDAQ:OREX), Lululemon ... - KC Register
06/09/16 06:01 PMOrexigen Therapeutics, Inc. (NASDAQ:OREX) Reshuffles Its Management - Journal Transcript
06/09/16 08:40 AMHealthcare Unusual Volume: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Immune Pharmaceuticals, Inc. (NASDAQ ... - KC Register
06/09/16 08:40 AMBRIEF-Orexigen Therapeutics promotes Tom Cannell to COO, Jason Keyes to CFO - Reuters
06/09/16 08:40 AMAnalyst Opinions on: Kinder Morgan, Inc. (NYSE:KMI), Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Beacon Chronicle
06/09/16 08:40 AMEarnings Estimates Analysis: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - News Oracle
06/09/16 08:40 AMOrexigen Therapeutics Inc. (OREX) Jumps 51.56% on June 08 - Equities.com
06/09/16 07:58 AMOrexigen Stock Gains More than 50% on Markman Hearing -
06/09/16 07:28 AMOrexigen Stock Gains More than 50% on Markman Hearing - Zacks.com - News OracleOrexigen Stock Gains More than 50% on Markman HearingZacks.comOrexigen Therapeutics, Inc.'s (OREX - Analyst Report) shares shot up 51.6% on a favorable Markman hearing in the company's patent infringement lawsuit against Actavis. In the Markman ruling, Judge Richard G. Andrews adopted Orexigen's proposed ...Stocks: 5 things to know before the openCNNMoneyOrexigen Moves Up On Judge Ruling Regarding Patents - What Investors Need To ConsiderSeeking AlphaOrexigen Therapeutics (OREX) Receives Positive Markman Decision in Contrave Patent SpatStreetInsider.comNews Oracle -Zergwatch -aomarkets (registration) (blog) -The Postall 19 news articles »
06/08/16 06:06 PMOrexigen Therapeutics (OREX) Receives Positive Markman Decision in Contrave Patent Spat - StreetInsider.com
06/08/16 08:52 AMBRIEF-Orexigen Therapeutics reports favorable Markman ruling - * Orexigen Therapeutics reports favorable Markman ruling in contrave patent litigation
06/08/16 08:41 AMBRIEF-Orexigen Therapeutics reports favorable Markman ruling - Reuters
06/08/16 08:41 AMStock in the Spotlight: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - News Oracle
06/08/16 08:18 AMOrexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation - [at noodls] - SAN DIEGO, June 8, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim construction (Markman) ...
06/07/16 05:54 PMThe Two Most Buy Stocks: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Oclaro, Inc. (NASDAQ:OCLR) - Beacon Chronicle
06/05/16 05:41 PMOrexigen: Contrave Sales Stall - What Should Give Investors Pause - Seeking Alpha
06/03/16 02:33 PMETF’s with exposure to Orexigen Therapeutics, Inc. : June 3, 2016 -
06/03/16 08:34 AMStock Review and Earnings Check on Orexigen Therapeutics, Inc. (NASDAQ:OREX) - HNN - Stock Review and Earnings Check on Orexigen Therapeutics, Inc. (NASDAQ:OREX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Orexigen Therapeutics, Inc.and more »
06/02/16 06:03 PMBroker Analysis: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Share Trading News - Broker Analysis: Orexigen Therapeutics, Inc. (NASDAQ:OREX)Share Trading NewsBroker Analysis: Orexigen Therapeutics, Inc. (NASDAQ:OREX). By Brenton Akerman / in US Broker Ratings / on Thursday, 02 Jun 2016 11:12 AM / 0 Comments. The most recently updated broker views and price targets issued for Orexigen Therapeutics, Inc.
06/02/16 06:03 PMNews Sentiment For Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Investor Newswire - News Sentiment For Orexigen Therapeutics, Inc. (NASDAQ:OREX)Investor NewswireOrexigen Therapeutics, Inc. (NASDAQ:OREX) has been given a sentiment score of -0.29 by research firm. Coming to the sentiment scale, the impact score measured on daily basis stands on a 1-100 scale. This score is taken into account to get the ...and more »
06/01/16 06:08 PMStrong Sell Calls Count For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire - Strong Sell Calls Count For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0Investor NewswireAnalyst score was 3.17. A quarter ago, the mean score was 2.83 and 0 were Strong Sell recommendations. Strong Buy calls were 0, the buy calls were 0 and sell calls on Orexigen Therapeutics, Inc. (NASDAQ:OREX) were 1. The count of Hold ratings was 4.and more »
06/01/16 01:19 PMOrexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 08:37 AMNotable Analyst's Ranking Preview: Relypsa, Inc. (NASDAQ:RLYP) , Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Street Updates - Notable Analyst's Ranking Preview: Relypsa, Inc. (NASDAQ:RLYP) , Orexigen Therapeutics, Inc. (NASDAQ:OREX)Street UpdatesOn 5/31/2016, Relypsa, Inc. (NASDAQ:RLYP) ended trading session higher at $19.10 with +5.76%. The company traded a volume of 6.96 million shares as comparison to average volume of 2.7 million shares. During the 52 –week period, the stock's price ...Healthcare Stocks news Updates: Orexigen Therapeutics, Inc.(NASDAQ:OREX), Edwards Lifesciences Corp(NYSE:EW)NYSE Journal (press release)all 3 news articles »
05/31/16 09:06 AMShare Rating Focus on Orexigen Therapeutics, Inc. (NASDAQ:OREX) - HNN - Share Rating Focus on Orexigen Therapeutics, Inc. (NASDAQ:OREX)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 3.2 on shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX). Covering analysts ...and more »
05/31/16 09:06 AMEarnings in Focus: HCA Holdings (HCA),Orexigen Therapeutics (OREX) - Beacon Chronicle - Beacon ChronicleEarnings in Focus: HCA Holdings (HCA),Orexigen Therapeutics (OREX)Beacon ChronicleLast Trade: The Company closed its last session at $ 0.417 Friday with the gain of 1.68%. The market capitalization of the company is $ 61.71Million, with the average Volume of $ 2.21 Million. The stock currently has its 52-Week High range of $ 5.19 ...and more »
05/30/16 11:17 PMOrexigen Therapeutics Co-Founder Resigns From the Board of Directors - San Diego drugmaker Orexigen Therapeutics Inc. announced May 27 that Dr. Eckard Weber, the company’s co-founder and former chairman, has resigned from the board of directors. Weber served as chairman for over a decade, from 2002 to earlier this year.
05/30/16 11:17 PMOrexigen Therapeutics, Inc. (NASDAQ:OREX) 1-Year High At $5.1900 - Investor Newswire - share market updates (press release)Orexigen Therapeutics, Inc. (NASDAQ:OREX) 1-Year High At $5.1900Investor NewswireThis study showed that Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock's 52-week range is $0.3500 – 5.1900. The last close was $0.4169 and volume was 1377194. The short ratio is 9.6600. Orexigen Therapeutics, Inc. (NASDAQ:OREX), a NMS public ...HC Stocks Movements: Orexigen Therapeutics, Inc. (NASDAQ:OREX), HCA Holdings Inc (NYSE:HCA)share market updates (press release)Active Stocks Need to Consider- Orexigen Therapeutics (NASDAQ:OREX), Portola Pharmaceuticals (PTLA), Endo ...Seneca GlobeOrexigen Therapeutics, Inc. (NASDAQ:OREX) Broker Price Targets For The Coming WeekShare Trading NewsFranklin Independent -Market Digest -Benchmark Monitorall 9 news articles »
05/29/16 12:45 AMShining Stocks in News Recap- Yum! Brands (NYSE:YUM), Orexigen Therapeutics (NASDAQ:OREX), Portola ... - Seneca Globe - Shining Stocks in News Recap- Yum! Brands (NYSE:YUM), Orexigen Therapeutics (NASDAQ:OREX), Portola ...Seneca GlobeYum! Brands, Inc. (NYSE:YUM) luring passive investments, as shares inched up 0.17% ended at $82.59 as the stock held volume of 1.83 Million as compared to average daily volume of 3025.13. Yum! Brands subs commence offering of $2.3 billion aggregate ...
05/27/16 07:42 PMOrexigen Therapeutics (OREX) Announces Resignation of Director, co-Founder Weber - StreetInsider.com - Orexigen Therapeutics (OREX) Announces Resignation of Director, co-Founder WeberStreetInsider.comOrexigen Therapeutics, Inc. (Nasdaq: OREX) announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. Dr. Weber served as Chairman from 2002 until earlier this year. From November 2008 ...Orexigen Therapeutics Says Co-Founder and Former Chairman Eckard Weber Resigns From Board (NASDAQ:OREX)Sonoran Weekly ReviewUpgrades And Downgrades For Orexigen Therapeutics, Inc. (NASDAQ:OREX)Risers & FallersHow Many Orexigen Therapeutics, Inc. (NASDAQ:OREX)'s Analysts Are Bearish?The Postall 4 news articles »
05/27/16 03:10 PMOrexigen Announces Upcoming Presentations at European Obesity Summit 2016 - [PR Newswire] - SAN DIEGO, May 27, 2016 /PRNewswire/ -- Orexigen Therapeutics (OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the European Obesity Summit 2016 at The Swedish Exhibition and Congress Centre in Gothenburg, Sweden on June 1-4, 2016. Nonclinical studies suggest that naltrexone and bupropion have effects on two separate areas of the brain involved in the regulation of food intake: the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system).
05/27/16 08:37 AMOrexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board - [at noodls] - SAN DIEGO, May 27, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. ...
05/27/16 08:07 AMOREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/26/16 02:31 PMEarnings Review and Stock Rundown for Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Orexigen Therapeutics, Inc. (NASDAQ:OREX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Orexigen Therapeutics, Inc. (NASDAQ:OREX) ...Hold Calls Count For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 4Enterprise Leaderall 296 news articles »
05/26/16 08:07 AMOrexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - [at noodls] - Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/25/16 02:24 PMStocks Performance Today: F.N.B. Corp (NYSE:FNB), Orexigen Therapeutics, Inc.(NASDAQ:OREX) - News Oracle - Stocks Performance Today: F.N.B. Corp (NYSE:FNB), Orexigen Therapeutics, Inc.(NASDAQ:OREX)News OracleThe stock gained2.86% and closed its last session at $13.32. The Company has the market capitalization of 2.77 Billion. The 52-Week Range ranges between $11.16 and $14.80. The stock traded with the Volume of 1.19 Million in the last trading day whereas ...and more »
About Orexigen Therapeutics

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company's product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER. The Company's product Contrave, is approved in the United States by the United States Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI), of around 30 kilograms per square meter (kg/m2) or greater (obese), or around 27 kilograms per square meter or greater (overweight) in the presence of at least one weight-related comorbid condition. The Company also submitted an application for marketing authorization with the European Medicines Agency (EMA) for Contrave under the name Mysimba.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OREX
  • CUSIP: 68616410
Key Metrics:
  • Previous Close: $0.45
  • 50 Day Moving Average: $0.4331
  • 200 Day Moving Average: $0.9914
  • P/E Ratio: N/A
  • P/E Growth: 0.0100
  • Market Cap: $65.33M
  • Current Quarter EPS Consensus Estimate: $-0.5000 EPS
Additional Links:
Orexigen Therapeutics (NASDAQ:OREX) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha